National Cancer Institute Explained

Agency Name:National Cancer Institute (NCI)
Jurisdiction:Federal government of the United States
Headquarters:Office of the Director,
31 Center Drive, Building 31, Bethesda, Maryland,
20814
Chief1 Name:Kimryn Rathmell
Chief1 Position:Director
Parent Department:United States Department of Health and Human Services
Parent Agency:National Institutes of Health
Child1 Agency:NCI Shady Grove Campus
Child2 Agency:NCI at NIH Bethesda Campus
Child3 Agency:NCI Frederick Campus
Footnotes:[1] [2] [3] [4] [5]

The National Cancer Institute (NCI) coordinates the United States National Cancer Program and is part of the National Institutes of Health (NIH), which is one of eleven agencies that are part of the U.S. Department of Health and Human Services. The NCI conducts and supports research, training, health information dissemination, and other activities related to the causes, prevention, diagnosis, and treatment of cancer; the supportive care of cancer patients and their families; and cancer survivorship.

NCI is the oldest and has the largest budget and research program of the 27 institutes and centers of the NIH ($6.9 billion in 2020).[6] It fulfills the majority of its mission via an extramural program that provides grants for cancer research. Additionally, the National Cancer Institute has intramural research programs in Bethesda, Maryland, and at the Frederick National Laboratory for Cancer Research[7] at Fort Detrick in Frederick, Maryland. The NCI receives more than in funding each year.[8]

The NCI supports a nationwide network of 72 NCI-designated Cancer Centers with a dedicated focus on cancer research and treatment[9] and maintains the National Clinical Trials Network.[10]

History

Timeline

Anti-cancer drug investigations

Organization

The NCI is divided into several divisions and centers.[18]

Intramural

The CCR includes approximately 250 internal NCI research groups in Frederick and Bethesda.[19]

DCEG is made up of eight branches within the Trans-divisional Research Program.[20]

Extramural

DCB oversees approximately 2000 grants per year in the areas of cancer cell biology; cancer immunology, hematology, and etiology; DNA and chromosome aberrations; structural biology and molecular applications; tumor biology and microenvironment; and tumor metastasis.[21] "Special Research Programs" falling under the aegis of the DCB include: Physical Sciences-Oncology Network, Cancer Systems Biology Consortium, Oncology Models Forum, Barrett's Esophagus Translational Research Network, New Approaches to Synthetic Lethality for Mutant KRAS-Dependent Cancers, Molecular and Cellular Characterization of Screen-Detected Lesions, Fusion Oncoproteins in Childhood Cancers, and Cancer Tissue Engineering Collaborative.[22]

DCTD supports eight research programs: The Biometric Research Program, The Cancer Diagnosis Program, The Cancer Imaging Program, The Cancer Therapy Evaluation Program, The Developmental Therapeutics Program, The Radiation Research Program, The Translational Research Program, and The Office of Cancer Complementary and Alternative Medicine.[23]

DEA processes and supports the thousands of grant applications NCI receives each year and compiles reports on the progress of research funded by the NCI's programs.[24]

Office of the director

CCG was created in 2011 and is responsible for management of The Cancer Genome Atlas and cancer genomics initiatives.

In the 1990s, the Unconventional Innovation Program was created to integrate interdisciplinary technology research with biological applications. It was reorganized in 2004 as the CSSI.[25]

Programs

NCI-designated Cancer Centers

The NCI-designated Cancer Centers are one of the primary arms in the NCI's mission in supporting cancer research. There are currently 72 so-designated centers; 9 cancer centers, 56 comprehensive cancer centers, and 7 basic laboratory cancer centers. NCI supports these centers with grant funding in the form of P30 Cancer Center Support Grants to support shared research resources and interdisciplinary programs. Additionally, faculty at the cancer centers receive approximately 75% of the grant funding awarded by the NCI to individual investigators.[9] [26]

The NCI cancer centers program was introduced in 1971 with 15 participating institutions.[27]

National Clinical Trials Network

The National Clinical Trials Network (NCTN) was formed in 2014, from the Cooperative Group program to modernize the existing system to support precision medicine clinical trials. With precision medicine, many patients must be screened to determine eligibility for treatments in development.

Lead Academic Participating Sites (LAPS) were chosen at 30 academic institutions for their ability to conduct clinical trials and screen a large number of participants and awarded grants to support the infrastructure and administration required for clinical trials. Most LAPS grant recipients are also NCI-designated cancer centers.[10] NCTN also stores surgical tissue from patients in a nationwide network of tissue banks at various universities.[28]

Developmental Therapeutics Program

The NCI Development Therapeutics Program (DTP) provides services and resources to the academic and private-sector research communities worldwide to facilitate the discovery and development of new cancer therapeutic agents.[29]

Under the label "Discovery & Development Services" several services are offered, among them the NCI-60 human cancer cell line screen and the Molecular Target Program.[30]

In the Molecular Target Program thousands of molecular targets have been measured in the NCI panel of 60 human tumor cell lines. Measurements include protein levels, RNA measurements, mutation status and enzyme activity levels.[31]

NCI-60 Human Tumor Cell Lines Screen

The evolution of strategies at the NCI illustrates the changes in screening that have resulted from advances in cancer biology. The Developmental Therapeutics Program (DTP) operates a tiered anti-cancer compound screening program with the goal of identifying novel chemical leads and biological mechanisms. The DTP screen is a three phase screen which includes: an initial screen which first involves a single dose cytotoxicity screen with the 60 cell line assay. Those passing certain thresholds are subjected to a 5 dose screen of the same 60 cell-line panel to determine a more detailed picture of the biological activity. A second phase screen establishes the maximum tolerable dosage and involves in vivo examination of tumor regression using the hollow fiber assay. The third phase of the study is the human tumor xenograft evaluation.

Active compounds are selected for testing based on several criteria: disease type specificity in the in vitro assay, unique structure, potency, and demonstration of a unique pattern of cellular cytotoxicity or cytostasis, indicating a unique mechanism of action or intracellular target.

A high correlation of cytotoxicity with compounds of known biological mechanism is often predictive of the drugs mechanism of action and thus a tool to aid in the drug development and testing. It also tells if there is any unique response of the drug which is not similar to any of the standard prototype compounds in the NCI database.

Leadership

Portrait Director Tenure Notes
Carl Voegtlin[32] January 13, 1938 – July 31, 1943
Roscoe Roy SpencerAugust 1, 1943 – July 1, 1947
July 1, 1947 – April 6, 1948 Served as the seventh Surgeon General of the United States from 1948 to 1956.
May 15, 1948 – July 1, 1960
Kenneth Milo EndicottJuly 1, 1960 – November 10, 1969
Carl Gwin BakerJuly 13, 1970 – May 5, 1972
Frank Joseph Rauscher, Jr.May 5, 1972 – November 1, 1976
Arthur Canfield UptonJuly 29, 1977 – December 31, 1980
July 9, 1980 – September 1, 1988
December 22, 1988 – April 1, 1995
August 1, 1995 – September 30, 2001 11th Director, left to become President of the Case Institute of Health, Science, and Technology and later Executive Director of Global Health for the Bill & Melinda Gates Foundation.[33]
January 22, 2002 – June 10, 2006 12th Director, served from 2001 to 2006 before transitioning to a role as Commissioner of Food and Drugs.[34] [35]
September 15, 2006 – July 12, 2010 13th Director of the NCI, was nominated by President George W. Bush.[36]
July 12, 2010 – March 31, 2015 Co-winner of the Nobel Prize for studies of the genetic basis of cancer.[37] He was director of the National Institutes of Health from 1993 to 1999.
Norman E. SharplessOctober 17, 2017 – April 30, 2022 15th Director of the NCI.[38] [39] Transitioned to acting Commissioner of Food and Drugs in April 2019 and returned to NCI in November 2019.[40]
Monica BertagnolliOctober 17, 2022 – November 9, 202316th Director of NCI. First woman to hold the position.[41]
Kimryn RathmellDecember 18, 2023 – Present17th Director of NCI.[42]

Notable NCI faculty

Notable people

See also

Notes and references

General references

External links

Notes and References

  1. Web site: Director's Page . National Cancer Institute . en-US. 1 April 2015.
  2. Web site: NCI Director Dr. Norman E. Sharpless—Director's Page—Leadership—About NCI. 18 December 2018 . National Cancer Institute . en-US. 1 January 2019.
  3. Web site: Dr Norman Edward Sharpless, MD, NIH Enterprise Directory (NED). NED.NIH.gov. en-US. 2 January 2019.
  4. Web site: Visitor Information . National Cancer Institute . en-US. 2 January 2019. 1980-01-01.
  5. Book: NCI's Shady Grove Campus To Open In 2013. 2 April 2010. NIH Record. LXII. 7. en-US. The change is being made primarily due to the leases expiring at EPN, EPS and a few other buildings on Executive Blvd. The new buildings would house, in one facility, staff from those leased sites... NCI will continue to occupy floors 10 and 11 of Bldg. 31’s A wing, as well as much of the 3rd floor, and the NCI director will remain in 31. There are also many staff members in lab buildings and the Clinical Center on campus and a large presence in Frederick at Ft. Detrick.. 2 January 2019.
  6. Web site: Philippidis. Alex. 2020-09-21. Top 50 NIH-Funded Institutions of 2020. 2021-04-25. GEN - Genetic Engineering and Biotechnology News. en-US.
  7. Web site: NCI-Frederick: NCI-Frederick Home Page. NCIfCrf.gov. en-US. 18 December 2011. 16 October 2012. https://web.archive.org/web/20121016221828/http://www.ncifcrf.gov/. dead.
  8. Web site: Funding Trends . National Cancer Institute . en-US. 2018-12-20.
  9. Web site: NCI-Designated Cancer Centers. 5 April 2012. National Cancer Institute . en-US. July 26, 2019.
  10. Web site: NCI's National Clinical Trials Network . National Cancer Institute . en-US. 2014-05-29.
  11. National Cancer Institute Act: Text of the Act of August 5, 1937, creating the National Cancer Institute and authorizing an appropriation therefor. JNCI Journal of the National Cancer Institute. 1 August 1957. 19. 2. 133–137. en-US. 10.1093/jnci/19.2.133. 13502712 . 0027-8874.
  12. Web site: Statutes at Large Volume 50 (1937) Table of Contents; VOL. 49 – VOL. 51. LegisWorks.org. en-US. 1 January 2019. https://web.archive.org/web/20160306050456/http://www.legisworks.org/sal/50/toc50.html. 6 March 2016. dead.
  13. Web site: 75th Congress Public Law 244. LegisWorks.org. en-US. 1 January 2019. https://web.archive.org/web/20160307053937/http://www.legisworks.org/congress/75/publaw-244.pdf. 7 March 2016. dead.
  14. Web site: Statute 50 Page 559. LegisWorks.org. en-US. 1 January 2019. https://web.archive.org/web/20160317080953/http://legisworks.org/sal/50/stats/STATUTE-50-Pg559.pdf. 17 March 2016. dead.
  15. Book: December 13, 2016—Important Events in NCI History—National Cancer Institute (NCI). 18 October 2017. NIH Almanac. en-US. 1 January 2019.
  16. News: National Cancer Chief, Ned Sharpless, Named F.D.A.'s Acting Commissioner. Kaplan. Sheila. 2019-03-12. The New York Times. 2019-12-04. en-US. 0362-4331.
  17. Web site: Statement on the return of Dr. Ned Sharpless as NCI Director . Collins . Francis . Francis Collins . November 1, 2019 . The NIH Director . December 3, 2019.
  18. Web site: NCI Organization. National Cancer Institute. 1980-01-01.
  19. Web site: About CCR. 21 July 2014.
  20. Web site: DCEG Home. Division of Cancer Epidemiology and Genetics – National Cancer Institute. 1980-01-01.
  21. Web site: DCB Research Portfolio. National Cancer Institute. 2016-08-08.
  22. Web site: Division of Cancer Biology. National Cancer Institute. 2016-08-08.
  23. Web site: About DCTD – DCTD. dctd.cancer.gov.
  24. Web site: About NCI Division of Extramural Activities. deainfo.nci.nih.gov.
  25. Web site: History – Center for Strategic Scientific Initiatives (CSSI). cssi.cancer.gov. 2017-09-28. 2017-09-29. https://web.archive.org/web/20170929001136/https://cssi.cancer.gov/about/history. dead.
  26. Web site: OCC Homepage – OCCWebApp 2.1.0. cancercenters.cancer.gov.
  27. Web site: History of the NCI Cancer Centers Program. National Cancer Institute. 2012-08-13.
  28. Web site: NCTN Biospecimen Banks . 2024-01-22 . nctnbanks.cancer.gov . en.
  29. Web site: Welcome to the Developmental Therapeutics Program . . National Cancer Institute . 6 January 2018.
  30. Web site: Discovery & Development Services . 26 August 2015 . . National Cancer Institute . 6 January 2018.
  31. Web site: Molecular Targets . 12 May 2015 . . National Cancer Institute . 7 January 2018.
  32. Web site: National Cancer Institute (NCI). 7 July 2015.
  33. Web site: Dr. Richard D. Klausner Named Executive Director of Global Health for Bill & Melinda Gates Foundation.
  34. U.S. Congress . 7 December 2006 . Executive Session . Congressional Record . 152 . 134 . S11404–29, S11447–51 . 2006-12-12.
  35. Web site: U.S. Senate: U.S. Senate Roll Call Votes 109th Congress – 2nd Session. www.senate.gov.
  36. Web site: Emergent Biosolutions – Board of Directors bio . 2013-12-06.
  37. Web site: Director's Page – National Cancer Institute (Archive) . Cancer.gov . 2015-04-02 . bot: unknown . https://wayback.archive-it.org/5574/20150331220844/http://www.cancer.gov/aboutnci/director/messages/harold-varmus-resignation . 2015-03-31 .
  38. Web site: NCI Director Dr. Norman E. Sharpless—Director's Page—Leadership—About NCI. 18 December 2018 . National Cancer Institute . en-US. 1 January 2019.
  39. Web site: Dr Norman Edward Sharpless, MD, NIH Enterprise Directory (NED). NED.NIH.gov. en-US. 2 January 2019.
  40. Web site: NCI Director Dr. Norman E. Sharpless. 2017-10-17. National Cancer Institute. en. 2020-02-12.
  41. Web site: 2022-10-03 . Monica Bertagnolli becomes NCI director - NCI . 2022-10-21 . www.cancer.gov . en.
  42. Web site: 2023-12-18 . W. Kimryn Rathmell begins work as 17th director of the National Cancer Institute . 2023-12-26 . www.cancer.gov . en.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "National Cancer Institute".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.